Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
277 Leser
Artikel bewerten:
(1)

Y-Prime, LLC: YPrime Releases Inaugural ESG Report, Reinforcing Commitment to Responsible Innovation in Clinical Research

MALVERN, Pa., Sept. 23, 2025, a proven leader in clinical trial technology, today announced the release of its first Environmental, Social, and Governance (ESG) Report. The report highlights measurable progress across environmental stewardship, social impact, and governance practices, reflecting the company's long-standing belief that responsible innovation drives long-term business value.

The 2024 ESG Report details YPrime's progress in embedding sustainability into its operations, product platforms, and strategic partnerships. As clinical trials become more complex and globally distributed, YPrime is focused on advancing health equity, reducing its environmental footprint, and strengthening ethical practices to deliver better clinical trial outcomes for patients, sites, and sponsors.

Key Highlights from the 2024 ESG Report Include:

  • Global Recognition: Awarded an EcoVadis Bronze Medal (https://www.yprime.com/yprime-earns-ecovadis-rating-advancing-sustainable-clinical-trials/) (placing YPrime in the top 35% of 150,000+ companies) and earned a B score on its first Carbon Disclosure Project (CDP) submission, outperforming life sciences industry averages across all climate categories. The company is also a proud member of the United Nations Global Compact (https://www.yprime.com/yprime-commits-to-united-nations-global-compact-pledging-to-align-its-sustainable-business-practices-with-un-goals/), reinforcing its alignment with global sustainability principles.
  • Commitment to Sustainability: YPrime has adopted a comprehensive environmental policy centered on digital-first, low-waste operations and science-based targets. YPrime has already achieved zero direct (Scope 1) greenhouse gas emissions and is actively reducing indirect (Scope 2 and 3) emissions.
  • Inclusive Workforce: 54% of employees identify as women, and 42% of 2024 management-level hires were women, underscoring YPrime's commitment to equity in leadership.

"At YPrime, responsibility and performance go hand in hand," said Lindsay Daniel, Chief Human Resources Officer at YPrime. "This report underscores the progress we've made-and the work still ahead-as we strengthen transparency, sustainability, and equity. Together with our partners, we're shaping clinical research that is not only faster and smarter, but also greener and more inclusive."

The report outlines YPrime's future commitments, including submitting near-term Science Based Targets initiative (SBTi) goals in 2025, pursuing ISO 27001 certification, and achieving net-zero emissions by 2050.

"ESG is no longer optional-it is core to how we operate and innovate," said Paulo Limgenco, Vice President of Business Operations and ESG Strategy Lead at YPrime. "This report sets a strong foundation for accountability and continuous improvement. It reflects how deeply ESG is integrated into our platforms, our partnerships, and our culture."

The 2024 ESG Report aligns with the UN Global Compact and supports the Sustainable Development Goals most relevant to YPrime's mission, including SDG 3 (Good Health and Well-Being), SDG 10 (Reduced Inequalities), and SDG 13 (Climate Action).

To read the full report, visit www.yprime.com/esg-report-2024.

About YPrime
YPrime simplifies clinical trials with eCOA, IRT, and eConsent solutions that combine speed, flexibility, and quality. The YPrime eCOA platform enhances participant compliance with an intuitive app and easy-to-use design, streamlines site workflows through a powerful eCOA portal, integrates seamlessly with connected devices, and supports sponsors with dashboards for better decision-making. AI-supported eCOA localization accelerates globalization, while pre-validated and configurable eCOA and IRT deliver faster study startup with quality metrics above industry standards. Trusted by top pharma leaders and emerging biotech companies alike, YPrime blends deep industry expertise and innovation to deliver reliable solutions. With nearly two decades of proven success, solutions in 250+ languages, and support in 100+ countries, YPrime is your partner to solve clinical research challenges with certainty. Visit www.yprime.comor email marketing@yprime.com.

Media Contact
Grazia Mohren
Senior Vice President, Marketing, YPrime
marketing@yprime.com


© 2025 GlobeNewswire (Europe)
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.